Drug Profile


Alternative Names: Adcirca; Cialis; GF 196960; IC 351; LY450190; Zalutia

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline; ICOS Corporation
  • Developer Eli Lilly; Gilead Sciences; GlaxoSmithKline; ICOS Corporation; Northwestern University; United Therapeutics Corporation
  • Class Benzodioxoles; Carbolines; Erectile dysfunction therapies; Indoles; Small molecules
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Benign prostatic hyperplasia; Erectile dysfunction; Pulmonary arterial hypertension
  • Phase III Duchenne muscular dystrophy
  • Clinical Phase Unknown Raynaud's disease
  • Discontinued Angina pectoris; Female sexual dysfunction; Gastroparesis; Heart failure

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 26 Feb 2016 Eli Lilly terminates a phase-III trial in Duchenne muscular dystrophy (in children and adolescents) in USA, Canada, Argentina, Belgium, France, Italy, Netherlands, Spain, United Kingdom, Russia, Puerto Rico, South Korea and Taiwan due to lack of efficacy (NCT01865084)
  • 01 Dec 2015 Eli Lilly completes a phase III trial in Benign prostatic hyperplasia and Erectile dysfunction in China (NCT01937871)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top